Skip to main content
NCBI home page
Applied and Environmental Microbiology logoLink to Applied and Environmental Microbiology
. 1997 Apr;63(4):1307–1311. doi: 10.1128/aem.63.4.1307-1311.1997

Purification and Characterization of a Lovastatin Esterase from Clonostachys compactiuscula

T G Schimmel, W S Borneman, M J Conder
PMCID: PMC1389545  PMID: 16535567

Abstract

An esterase from the fungus Clonostachys compactiuscula selectively hydrolyzes lovastatin, a clinically useful antihypercholesterolemic agent. Lovastatin or lovastatin-related compounds were required to induce the activity of the lovastatin 8(prm1)-((alpha)-methylbutyryloxy) esterase. The 46-kDa esterase was purified from mycelial extracts by centrifugation and a single anion-exchange chromatographic separation. Maximal lovastatin esterase activity was found at pH 9.0 to 9.6 and at 25 to 30(deg)C. The addition of 5 to 20% methanol resulted in greater lovastatin hydrolysis, while the addition of other solvents (ethanol, isopropanol, butanol, ethyl acetate, isopropyl acetate, or tetrahydrofuran) decreased hydrolysis. Lovastatin was selectively hydrolyzed even in the presence of an excess of simvastatin, another antihypercholesterolemic agent that is structurally very similar to lovastatin. This lovastatin 8(prm1)-((alpha)-methylbutyryloxy) esterase can be used to prepare a core intermediate for the generation of novel antihypercholesterolemic agents or to purify simvastatin prepared by C methylation of the 2(S)-methylbutyryloxy side chain of lovastatin.

Full Text

The Full Text of this article is available as a PDF (687.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts A. W. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988 Nov 11;62(15):10J–15J. doi: 10.1016/0002-9149(88)90002-1. [DOI] [PubMed] [Google Scholar]
  2. Blankenhorn D. H., Azen S. P., Kramsch D. M., Mack W. J., Cashin-Hemphill L., Hodis H. N., DeBoer L. W., Mahrer P. R., Masteller M. J., Vailas L. I. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993 Nov 15;119(10):969–976. doi: 10.7326/0003-4819-119-10-199311150-00002. [DOI] [PubMed] [Google Scholar]
  3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  4. CLARIDGE C. A., GOUREVITCH A., LEIN J. Bacterial penicillin amidase. Nature. 1960 Jul 16;187:237–238. doi: 10.1038/187237a0. [DOI] [PubMed] [Google Scholar]
  5. Casy A. F., Lipczynski A. 8-Hydroxypenillic acid: NMR characteristics and facile formation from 6-aminopenicillanic acid. J Pharm Pharmacol. 1994 Jun;46(6):533–534. doi: 10.1111/j.2042-7158.1994.tb03848.x. [DOI] [PubMed] [Google Scholar]
  6. Endo A., Kuroda M., Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo) 1976 Dec;29(12):1346–1348. doi: 10.7164/antibiotics.29.1346. [DOI] [PubMed] [Google Scholar]
  7. Endo A. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo) 1979 Aug;32(8):852–854. doi: 10.7164/antibiotics.32.852. [DOI] [PubMed] [Google Scholar]
  8. Faulds C. B., Williamson G. Ferulic acid esterase from Aspergillus niger: purification and partial characterization of two forms from a commercial source of pectinase. Biotechnol Appl Biochem. 1993 Jun;17(Pt 3):349–359. [PubMed] [Google Scholar]
  9. Gunde-Cimerman N., Plemenitas A., Cimerman A. Pleurotus fungi produce mevinolin, an inhibitor of HMG CoA reductase. FEMS Microbiol Lett. 1993 Nov 1;113(3):333–337. doi: 10.1111/j.1574-6968.1993.tb06536.x. [DOI] [PubMed] [Google Scholar]
  10. Hoffman W. F., Alberts A. W., Anderson P. S., Chen J. S., Smith R. L., Willard A. K. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin. J Med Chem. 1986 May;29(5):849–852. doi: 10.1021/jm00155a040. [DOI] [PubMed] [Google Scholar]
  11. Komagata D., Yamashita H., Endo A. Microbial conversion of compactin (ML-236B) to ML-236A. J Antibiot (Tokyo) 1986 Nov;39(11):1574–1577. doi: 10.7164/antibiotics.39.1574. [DOI] [PubMed] [Google Scholar]
  12. Krauss R. M. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol. 1994 Oct;5(5):339–349. doi: 10.1097/00041433-199410000-00005. [DOI] [PubMed] [Google Scholar]
  13. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  14. Linden J., Samara M., Decker S., Johnson E., Boyer M., Pecs M., Adney W., Himmel M. Purification and characterization of an acetyl esterase from Aspergillus niger. Appl Biochem Biotechnol. 1994 Spring;45-46:383–393. doi: 10.1007/BF02941813. [DOI] [PubMed] [Google Scholar]
  15. Luengo J. M. Enzymatic synthesis of hydrophobic penicillins. J Antibiot (Tokyo) 1995 Nov;48(11):1195–1212. doi: 10.7164/antibiotics.48.1195. [DOI] [PubMed] [Google Scholar]
  16. Plosker G. L., McTavish D. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs. 1995 Aug;50(2):334–363. doi: 10.2165/00003495-199550020-00009. [DOI] [PubMed] [Google Scholar]
  17. Stokker G. E., Alberts A. W., Gilfillan J. L., Huff J. W., Smith R. L. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 5. 6-(Fluoren-9-yl)- and 6-(fluoren-9-ylidenyl)-3,5-dihydroxyhexanoic acids and their lactone derivatives. J Med Chem. 1986 May;29(5):852–855. doi: 10.1021/jm00155a041. [DOI] [PubMed] [Google Scholar]
  18. Tobert J. A. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation. 1987 Sep;76(3):534–538. doi: 10.1161/01.cir.76.3.534. [DOI] [PubMed] [Google Scholar]
  19. Vanwetswinkel S., Fastrez J., Marchand-Brynaert J. Synthesis of new sulfonylamido-penicillanic acid sulfones inhibitors of beta-lactamases. J Antibiot (Tokyo) 1994 Sep;47(9):1041–1051. doi: 10.7164/antibiotics.47.1041. [DOI] [PubMed] [Google Scholar]
  20. Walker J. F., Tobert J. A. The clinical efficacy and safety of lovastatin and MK-733--an overview. Eur Heart J. 1987 Aug;8 (Suppl E):93–96. doi: 10.1093/eurheartj/8.suppl_e.93. [DOI] [PubMed] [Google Scholar]
  21. Waters D., Higginson L., Gladstone P., Kimball B., Le May M., Boccuzzi S. J., Lespérance J. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994 Mar;89(3):959–968. doi: 10.1161/01.cir.89.3.959. [DOI] [PubMed] [Google Scholar]

Articles from Applied and Environmental Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES